Show simple item record

dc.contributor.authorTravis, Lois B.
dc.contributor.authorRabkin, Charles S.
dc.contributor.authorBrown, Linda Morris
dc.contributor.authorAllan, James M.
dc.contributor.authorAlter, Blanche P.
dc.contributor.authorAmbrosone, Christine B.
dc.contributor.authorBegg, Colin B.
dc.contributor.authorCaporaso, Neil
dc.contributor.authorChanock, Stephen
dc.contributor.authorDeMichele, Angela
dc.contributor.authorFigg, William Douglas
dc.contributor.authorGospodarowicz, Mary K.
dc.contributor.authorHall, Eric J.
dc.contributor.authorHisada, Michie
dc.contributor.authorInskip, Peter
dc.contributor.authorKleinerman, Ruth
dc.contributor.authorLittle, John B.
dc.contributor.authorMalkin, David
dc.contributor.authorNg, Andrea K.
dc.contributor.authorOffit, Kenneth
dc.contributor.authorPui, Ching-Hon
dc.contributor.authorRobison, Leslie L.
dc.contributor.authorRothman, Nathaniel
dc.contributor.authorShields, Peter G.
dc.contributor.authorStrong, Louise
dc.contributor.authorTaniguchi, Toshiyasu
dc.contributor.authorTucker, Margaret A.
dc.contributor.authorGreene, Mark H.
dc.date.accessioned2009-05-25T07:56:36Z
dc.date.available2009-05-25T07:56:36Z
dc.date.issued2006-01-04
dc.identifier.citationJ. Natl. Cancer Inst. 2006, 98 (1):15-25en
dc.identifier.issn1460-2105
dc.identifier.pmid16391368
dc.identifier.doi10.1093/jnci/djj001
dc.identifier.urihttp://hdl.handle.net/10146/68855
dc.descriptionKEYWORDS - CLASSIFICATION: adverse effects;Antineoplastic Agents;biomarkers of individual susceptibility: validation;Biotechnology;cancer epidemiology;chemically induced;Carcinogens;Case-Control Studies;Clinical Trials;Cohort Studies;Congresses;drug therapy;epidemiology;etiology;genetics;Genetic Predisposition to Disease;Humans;methods;mortality;Medical Informatics;Multicenter Studies;Neoplasms;Neoplasms,Radiation-Induced;Neoplasms,Second Primary;radiotherapy;Radiotherapy;Registries;Research;statistics & numerical data;Specimen Handling;Survivors;Syndrome;United States.en
dc.description.abstractCancer survivors constitute 3.5% of the United States population, but second primary malignancies among this high-risk group now account for 16% of all cancer incidence. Although few data currently exist regarding the molecular mechanisms for second primary cancers and other late outcomes after cancer treatment, the careful measurement and documentation of potentially carcinogenic treatments (chemotherapy and radiotherapy) provide a unique platform for in vivo research on gene-environment interactions in human carcinogenesis. We review research priorities identified during a National Cancer Institute (NCI)-sponsored workshop entitled "Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers." These priorities include 1) development of a national research infrastructure for studies of cancer survivorship; 2) creation of a coordinated system for biospecimen collection; 3) development of new technology, bioinformatics, and biomarkers; 4) design of new epidemiologic methods; and 5) development of evidence-based clinical practice guidelines. Many of the infrastructure resources and design strategies that would facilitate research in this area also provide a foundation for the study of other important nonneoplastic late effects of treatment and psychosocial concerns among cancer survivors. These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer.
dc.language.isoenen
dc.relation.urlhttp://jnci.oxfordjournals.org/cgi/content/full/98/1/15en
dc.subject.meshAntineoplastic Agents
dc.subject.meshBiotechnology
dc.subject.meshCarcinogens
dc.subject.meshCase-Control Studies
dc.subject.meshClinical Trials as Topic
dc.subject.meshCohort Studies
dc.subject.meshCongresses as Topic
dc.subject.meshGenetic Predisposition to Disease
dc.subject.meshHumans
dc.subject.meshMedical Informatics
dc.subject.meshMulticenter Studies as Topic
dc.subject.meshNeoplasms
dc.subject.meshNeoplasms, Radiation-Induced
dc.subject.meshNeoplasms, Second Primary
dc.subject.meshRadiotherapy
dc.subject.meshRegistries
dc.subject.meshSpecimen Handling
dc.subject.meshSurvivors
dc.subject.meshSyndrome
dc.subject.meshUnited States
dc.titleCancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.en
dc.typeArticleen
dc.identifier.journalJournal of the National Cancer Instituteen
html.description.abstractCancer survivors constitute 3.5% of the United States population, but second primary malignancies among this high-risk group now account for 16% of all cancer incidence. Although few data currently exist regarding the molecular mechanisms for second primary cancers and other late outcomes after cancer treatment, the careful measurement and documentation of potentially carcinogenic treatments (chemotherapy and radiotherapy) provide a unique platform for in vivo research on gene-environment interactions in human carcinogenesis. We review research priorities identified during a National Cancer Institute (NCI)-sponsored workshop entitled "Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers." These priorities include 1) development of a national research infrastructure for studies of cancer survivorship; 2) creation of a coordinated system for biospecimen collection; 3) development of new technology, bioinformatics, and biomarkers; 4) design of new epidemiologic methods; and 5) development of evidence-based clinical practice guidelines. Many of the infrastructure resources and design strategies that would facilitate research in this area also provide a foundation for the study of other important nonneoplastic late effects of treatment and psychosocial concerns among cancer survivors. These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer.


Files in this item

Thumbnail
Name:
J NAT CANCER IST 15.pdf
Size:
238.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record